SI Stock Forecast & Price Target

Shoulder Innovations is positioned for durable upside because its clinical differentiation, led by the InSet system, addresses major complications in shoulder arthroplasty and has shown zero revisions over a 10+ year span in clinical literature, supporting surgeon adoption and share gains. Recent results showed revenue of about $17.2M, up 56.0% year over year, with unit growth of 48.9% and durable gross margins, while FY26 sales guidance was raised to $67M-$69M, implying 42% to 46% growth. The outlook is further strengthened by a broad pipeline that could expand the addressable market by $200M+ through fracture, metal sensitivity, and revision products, plus a robot expected for submission in the first half of next year that may deepen workflow advantages and future ASPs.

Shoulder Innovations is showing solid top-line momentum, with Q2 revenue of $17.2M up 56% and gross margin of 78.3% beating expectations, but the business still posted an adjusted EBITDA loss of about $8M, underscoring that scale has not yet translated into profitability. The company’s FY26 outlook for $67M-$69M in revenue implies continued growth, yet management flags seasonality, lower 3Q26 sales, potential 4Q ASP pressure from procedure mix, and higher operating expenses as a percentage of sales, all of which limit near-term earnings leverage. The bearish case is further reinforced by execution risk tied to slower surgeon adoption, softer shoulder market growth, faster-than-expected ASP erosion, delayed entry into new segments, and elevated spending needed to support expansion.